<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177448</url>
  </required_header>
  <id_info>
    <org_study_id>502.267</org_study_id>
    <nct_id>NCT02177448</nct_id>
  </id_info>
  <brief_title>BIBR 277 Capsule in Patients With Essential Hypertension</brief_title>
  <official_title>A Double-blind, Parallel-group Comparison Study of BIBR 277 Capsule in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The efficacy and safety of Telmisartan capsule in patients with essential hypertension were
      evaluated in comparison with Enalapril Maleate in the double blind trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">September 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antihypertensive effect</measure>
    <time_frame>every 2 weeks up to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of normalized blood pressure</measure>
    <time_frame>every 2 weeks up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the adverse event cough</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in blood pressure (mean systolic and diastolic blood pressure)</measure>
    <time_frame>every 2 weeks up to week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>BIBR277 and placebo matching enalapril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril and placebo matching BIBR277</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR277 low dose</intervention_name>
    <arm_group_label>BIBR277 and placebo matching enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR277 medium dose</intervention_name>
    <arm_group_label>BIBR277 and placebo matching enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR277 high dose</intervention_name>
    <arm_group_label>BIBR277 and placebo matching enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril low dose</intervention_name>
    <arm_group_label>Enalapril and placebo matching BIBR277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril medium dose</intervention_name>
    <arm_group_label>Enalapril and placebo matching BIBR277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril high dose</intervention_name>
    <arm_group_label>Enalapril and placebo matching BIBR277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BIBR277</intervention_name>
    <arm_group_label>Enalapril and placebo matching BIBR277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching enalapril</intervention_name>
    <arm_group_label>BIBR277 and placebo matching enalapril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ≥ 25 years of age

          -  Patient is either male or female

          -  Outpatient. Change to inpatient is not allowed during the study period

          -  Blood pressure is measured 3 times or more during the 4-week observation period; the
             last 2 measurements in the sitting position (intervals between measurements must be
             less than 4 weeks) are stabilized for both of systolic pressure (within +/- 30 mmHg)
             and diastolic pressure within +/- 15 mmHg) with the mean exceeding 160 mmHg for
             systolic and 95 mmHG for diastolic pressure

        Exclusion Criteria:

          -  Patient has severe hypertension (the last 2 measurements in the observation period
             exceed 120 mmHg in terms of diastolic blood pressure)

          -  Patient has secondary or malignant hypertension

          -  Patient has a history of severe cardiac failure, unstable angina, or myocardial
             infarction within previous six months

          -  Patient has atrioventricular conduction disturbance, atrial fibrillation or severe
             arrhythmia

          -  Patient has any symptoms of cerebrovascular disorder

          -  Patient has serious hepatic dysfunction (either GOT (glutamic-oxaloacetic
             transaminase) or GPT (glutamic-pyruvic transaminase) exceeds 100 U)

          -  Patient has renal dysfunction (serum creatinin ≥ 2.1 mg/dl)

          -  Patient has uncontrolled diabetic (either of the following tests exceeds the specified
             standards: fasting blood glucose exceeding 151 mg/dl or HbA1c exceeding 8%)

          -  Patient has a history of drug sensitivity to ACE (angiotensin converting enzyme)
             inhibitors and angiotensin II receptor antagonists

          -  Patient has a history of angioedema due to ACE inhibitors

          -  Patient has hyperkalemia (K exceeding 5.5 mEq/l)

          -  Patient has received enalapril just before the start of observation period

          -  Patient has received treatment with any other investigational drug(s) within three
             months of the start of observation period

          -  Patients is pregnant, breast-feeding, or possible pregnant, or wants to be pregnant
             during the study period

          -  Patient has any other condition that the investigator or subinvestigator feels would
             be inappropriate for the study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

